63,031 Shares in Pfizer Inc. $PFE Purchased by Arista Wealth Management LLC

Key Points

• Arista Wealth Management LLC has acquired a new stake in Pfizer Inc. by purchasing 63,031 shares valued at approximately $1,528,000 in the second quarter.
• Pfizer's stock is currently priced at $24.22 and has a market capitalization of $137.70 billion with a P/E ratio of 12.88.
• The company recently announced a quarterly dividend of $0.43 per share, set to be paid on December 1st, representing a yield of 7.1%.

Arista Wealth Management LLC acquired a new stake in Pfizer Inc. (NYSE:PFE - Free Report) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 63,031 shares of the biopharmaceutical company's stock, valued at approximately $1,528,000.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. GKV Capital Management Co. Inc. acquired a new position in Pfizer during the first quarter worth $27,000. Bayforest Capital Ltd purchased a new position in shares of Pfizer during the 1st quarter worth $28,000. North Capital Inc. acquired a new position in shares of Pfizer during the 1st quarter valued at about $28,000. Harbor Asset Planning Inc. purchased a new stake in shares of Pfizer in the second quarter valued at about $29,000. Finally, WPG Advisers LLC acquired a new stake in Pfizer during the first quarter worth about $35,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Stock Performance

Shares of PFE stock opened at $24.22 on Friday. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $29.53. The stock has a market capitalization of $137.70 billion, a PE ratio of 12.88, a P/E/G ratio of 0.81 and a beta of 0.55. The firm has a 50 day moving average of $24.89 and a two-hundred day moving average of $24.12.

Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping analysts' consensus estimates of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The firm had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. During the same period in the prior year, the firm earned $0.60 earnings per share. The business's quarterly revenue was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, research analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be issued a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, November 7th. This represents a $1.72 dividend on an annualized basis and a yield of 7.1%. Pfizer's dividend payout ratio (DPR) is presently 91.49%.

Analyst Ratings Changes

PFE has been the subject of several analyst reports. Wall Street Zen cut shares of Pfizer from a "buy" rating to a "hold" rating in a research note on Sunday, September 28th. Weiss Ratings reiterated a "hold (c-)" rating on shares of Pfizer in a report on Wednesday, October 8th. Morgan Stanley cut their target price on Pfizer from $33.00 to $32.00 and set an "equal weight" rating for the company in a research note on Friday, October 10th. Citigroup lifted their target price on Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a research report on Wednesday, August 6th. Finally, UBS Group reiterated a "neutral" rating and set a $28.00 price target on shares of Pfizer in a report on Wednesday, October 1st. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Pfizer has an average rating of "Hold" and an average price target of $28.13.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.